Human VEGF (Research Grade Bevacizumab Biosimilar) Antibody, R&D Systems™

Human Monoclonal Antibody

Catalog Number	Mfr. No.	Quantity
MAB9947SP	R&D Systems MAB9947SP	25 μg
MAB9947100	R&D Systems MAB9947100	100 μg

Description

VEGF Monoclonal specifically detects VEGF in Human samples. It is validated for Neutralization.

Specifications

• Antigen: VEGF
• Dilution: Neutralization 10-80 ng/mL
• Classification: Monoclonal
• Host Species: Human
• Formulation: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS.
• Gene ID (Entrez): 7422.0
• Isotype: IgG1
• Purification Method: Protein A or G purified from cell culture supernatant
• Content And Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C, as supplied. 1 month, 2 to 8 °C under sterile conditions after opening. 6 months, -20 to -70 °C under sterile conditions after opening.

• Clone: Hu101
• Applications: Neutralization
• Conjugate: Unconjugated
• Target Species: Human
• Gene Alias: MVCD1, VAS, vascular endothelial growth factor A, Vascular permeability factor, Vasculotropin, VEGFA, VEGF-A, VEGFMGC70609, VPF, VPFvascular endothelial growth factor
• Immunogen: Human VEGF-A
• Primary or Secondary: Primary
• Reconstitution: Reconstitute at 0.5 mg/mL in sterile PBS.
• Test Specificity: Detects human VEGF based on Bevacizumab therapeutic antibody. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab. This product is for research use only.